RenovaCare products are under development and not approved for sale in the United States.

Results may vary from person to person.

RenovaCare products are under development and not approved for sale in the United States.
Results may vary from person to person.

RenovaCare Awarded New Patents Allowing Greater Versatility of SkinGun™; Sterility in Field Environments; Spray Solutions to Now Include Targeted Cells, Drugs or Hormones

Roseland, NJ – November 19, 2020 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced the issuance of two new patents encompassing improvements to the SkinGun™, expanding its potential application beyond the surgical setting into the field, and allowing the use of liquid suspension solutions to include drugs, hormones, and other useful agents.

RenovaCare to Commence Investor Business and Financial Presentations; Webcast on October 29, 2020

Roseland, NJ – October 5, 2020 – RenovaCare, Inc. (Symbol: RCAR), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that Alan L. Rubino, Chief Executive Officer and President, has been elected to the additional role of Chairman of the Board of RenovaCare effective October 1, 2020.

RenovaCare to Present at BioNJ/JP Morgan/J&J BioPartnering Conference

Roseland, NJ – September 15, 2020 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that the Company will present at the tenth annual BioPartnering Conference, hosted by BioNJ and co-sponsored by J.P. Morgan and Johnson & Johnson Innovation, scheduled for October 6 – 7, 2020.

RenovaCare Receives FDA Conditional IDE Approval of CellMist™ System and SkinGun™ Device, Enabling Clinical Study for Safety and Feasibility

Roseland, NJ – August 11, 2020 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that the US Food and Drug Administration (FDA) conditionally approved the Company’s Investigational Device Exemption (IDE) application to conduct a clinical trial to evaluate the safety and feasibility of autologous stem cells rendered by its CellMist™ System from donor skin and applied topically with the SkinGun™ spray device for treatment of burn wounds.

RenovaCare Launches R&D Innovation Center (Berlin) for Organ & Tissue Regeneration

Roseland, NJ – July 1, 2020 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), today announced the official launch of its new RenovaCare R&D Innovation Center in Berlin, Germany, where the Company’s patented technologies for isolating and spraying self-donated stem cells to regenerate tissues and organs have been under development alongside new product initiatives.

RenovaCare Strengthens FDA Program with Leading U.S. Regulatory Group and Significant Investment

Roseland, NJ – May 28th, 2020 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that it has expanded its engagement with MCRA, the leading U.S. regulatory group for medical devices and biologics, to continue to advance the Company’s FDA program.